



**HAL**  
open science

## **Regenerative potential of primary adult human neural stem cells on micropatterned bioimplants boosts motor recovery**

Carole Davoust, Benjamin Plas, Amélie Bédurier, Boris Demain, Anne-Sophie Salabert, Jean Christophe Sol, Christophe Vieu, Laurence Vaysse, Isabelle Loubinoux

► **To cite this version:**

Carole Davoust, Benjamin Plas, Amélie Bédurier, Boris Demain, Anne-Sophie Salabert, et al.. Regenerative potential of primary adult human neural stem cells on micropatterned bioimplants boosts motor recovery . *Current Stem Cell Research & Therapy*, In press, 38p. hal-01618948v1

**HAL Id: hal-01618948**

**<https://laas.hal.science/hal-01618948v1>**

Submitted on 18 Oct 2017 (v1), last revised 12 Nov 2017 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

[Click here to view linked References](#)

# Regenerative potential of primary adult human neural stem cells on micropatterned bioimplants boosts motor recovery

Carole Davoust<sup>a</sup>, Benjamin Plas<sup>a,c</sup>, Amélie Bédurier<sup>b</sup>, Boris Demain<sup>a</sup>, Anne-Sophie Salabert<sup>a,c</sup>,

Jean Christophe Sol<sup>a,c</sup>, Christophe Vieu<sup>b</sup>, Laurence Vaysse<sup>a</sup>, Isabelle Loubinoux<sup>a</sup>

<sup>a</sup>ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France

<sup>b</sup>LAAS-CNRS, Université de Toulouse, CNRS, INSA, UPS, Toulouse, France

<sup>c</sup>Centre Hospitalier Universitaire de Toulouse; Pôle Neurosciences ; CHU Toulouse, France

Corresponding author

Isabelle Loubinoux

UMR1214 – Inserm/UPS – ToNIC

CHU PURPAN

Pavillon Baudot

Place du Dr Baylac

31024 Toulouse Cedex 3

France

Tel.: 33(5) 62 74 61 64

Fax: 33(5) 62 74 61 63

Email: [isabelle.loubinoux@inserm.fr](mailto:isabelle.loubinoux@inserm.fr)

Carole Davoust [carole.davoust@wanadoo.fr](mailto:carole.davoust@wanadoo.fr); Amélie Bédurier [amelie.beduer@gmail.com](mailto:amelie.beduer@gmail.com);

Boris Demain [boris.demain@gmail.com](mailto:boris.demain@gmail.com); Anne-Sophie Salabert [\[sophie.salabert@inserm.fr\]\(mailto:sophie.salabert@inserm.fr\); jean-christophe SOL \[jch.sol@gmail.com\]\(mailto:jch.sol@gmail.com\); Christophe Vieu](mailto:anne-</a></p></div><div data-bbox=)

[cvieu@laas.fr](mailto:cvieu@laas.fr); Laurence Vaysse [laurence.vaysse@inserm.fr](mailto:laurence.vaysse@inserm.fr); Isabelle Loubinoux :

[isabelle.loubinoux@inserm.fr](mailto:isabelle.loubinoux@inserm.fr).

**Running title:** hNSC-Implants for motor recovery

## **ABSTRACT:**

1  
2  
3 Background: The adult brain is unable to regenerate itself sufficiently after large injuries.  
4  
5 Therefore, hopes rely on therapies using neural stem cell or biomaterial transplantation to  
6  
7 sustain brain reconstruction. The aim of the present study was to evaluate the improvement in  
8  
9 sensorimotor recovery brought about by human primary adult NSCs in combination with  
10  
11 bioimplants. Methods: hNSCs were pre-seeded on implants micropatterned for neurite guidance  
12  
13 and inserted intracerebrally 2 weeks after a primary motor cortex lesion in rats. Long-term  
14  
15 behaviour was significantly improved after hNSC-Implants versus cell engraftment in the grip  
16  
17 strength test. MRI and immunohistological studies were conducted to elucidate the underlying  
18  
19 mechanisms of neuroimplants integration. Results: hNSC-Implants promoted tissue  
20  
21 reconstruction and limited hemispheric atrophy and glial scar expansion. After 3 months,  
22  
23 grafted hNSCs were detected on implants and expressed mature neuronal markers (NeuN,  
24  
25 MAP2, and SMI312). They also migrated over a short distance to the reconstructed and to the  
26  
27 perilesional tissues, where 26% integrated as mature neurons. Newly formed host neural  
28  
29 progenitors (nestin, DCX) colonized the implants, notably in the presence of hNSCs, and  
30  
31 participated to tissue reconstruction. The microstructured bioimplants sustained the guided  
32  
33 maturation of both grafted hNSCs and endogenous progenitors. Conclusions: these  
34  
35 immunohistological results are coherent with and could explain the late improvement observed  
36  
37 in sensorimotor recovery. These findings provide novel insights into the regenerative potential  
38  
39 of primary adult hNSCs combined with microstructured implants.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 **Keywords:** Brain injury, cell therapy, biomaterial, tissue engineering, sensorimotor recovery  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# 1. Background

The increasing number of neurological injuries over recent years has become a major public health problem. Cellular and neuronal loss may occur after traumatic brain injury, subarachnoid haemorrhage or stroke, leading to serious and sometimes fatal deficits. At present, none of the current available treatments allow for complete functional recovery in severely impaired patients with acquired deficits.

The adult brain still contains neural stem cells (NSCs), particularly in zones known as neurogenic niches [1]. In humans, the main neurogenic niches are the subventricular zone (SVZ) and the subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus [2]. These adult NSCs are capable of self-renewal [3] and can generate the three main lineages of the brain: neurons, astrocytes and oligodendrocytes [4], and have limited proliferation [5].

Interestingly, after a brain insult, adult neurogenesis is boosted [6] and neural stem cells are attracted to the damaged area [7,8] up to one year after the infarct [9]. Nonetheless, most of the newly formed progenitors fail to survive in the long term [10,11] or to differentiate into mature cells [12]. As the brain is unable to sufficiently regenerate itself, one potential solution is to develop cell replacement strategies. Several cell sources are potentially available for graft, including neural cell lines [13], embryonic stem cells [14], mesenchymal stem cells (MSCs) [15], and induced pluripotent stem (iPS) cells [16]. However, the first two raise ethical concerns, while the potential of the other two to differentiate into neuronal cells is still very low. [Mounting evidence shows the potential role of adult hNSCs in brain tissue regeneration after a cerebral lesion, even in humans](#) [7]. To study their potential, we chose to graft adult hNSCs. At present, the best sources of neural stem/progenitor cells in the adult brain are human biopsies of the SVZ and temporal lobe [17–19].

Once grafted, NSCs can contribute to the tissular reconstruction. They are also known to release neurotrophic and immunoprotective factors that promote the restoration of brain tissue and

1 prevent the damage from spreading [20]. Whatever the cell source, motor recovery is not  
2 complete in animal models [21], essentially owing to poor engraftment [22]. Tissue engineering  
3 could provide solutions in the form of 3D, to improve cell survival and differentiation [23].  
4 Maturation of grafted cells has been demonstrated to take months [24]. Therefore, non-  
5 degradable biomaterials have to be tested first to guarantee optimal neuronal differentiation.  
6 Biomaterials have been developed to locally deliver pharmacological growth factors such as  
7 VEGF (vascular endothelial growth factor) [15] and BDNF (brain derived neurotrophic factor)  
8 [25] to favour tissue reconstruction. Another approach consists in seeding cells, be they adult  
9 rat neural progenitor cells [26], human MSCs [22] or hNT2, a human neuronal cell line [27],  
10 on the scaffold before implantation, to enhance the potential effect of both grafted cells and  
11 biomaterials [27]. The challenge is still to find both a biomaterial adapted to neuronal  
12 differentiation and cell sources able to regenerate adult human brain in order to restore  
13 sensorimotor functions.

14 We have developed a new micropatterned PDMS (polydimethylsiloxane) device for brain tissue  
15 reconstruction. The design of these scaffolds and their dimensions have been optimized to allow  
16 for neuronal development, hNSC differentiation, and to align neurites along microchannels,  
17 thus favouring long-axon formation [28]. A pilot study have shown the feasibility of inserting  
18 these PDMS scaffolds combined with a neuronal cell line in a model of cortico-striatal injury  
19 [29].

20 In the present report, we assessed motor recovery following a cortico-striatal bioprosthesis  
21 consisting in the graft of primary hNSCs isolated from patient biopsies, pre-seeded on 3D  
22 micropatterned implants. The so-called neuro-implants were directly inserted dorso-ventrally  
23 in the infarct area 2 weeks after injury in a rat model. Cell integration, neuronal differentiation,  
24 cell migration and glial reaction were particularly studied using immunohistological  
25 approaches.

## 2. MATERIALS AND METHODS

### 2.1. hNSC-micropatterned bioimplant preparation

#### 2.1.1. Fabrication of 3D micropatterned PDMS implant

The implantable device, already described elsewhere [28,30], consisted of two PDMS micropatterned layers assembled (300  $\mu\text{m}$  thick) to form a 3D microstructured implant (2 x 4 mm). PDMS shows excellent resistance to biodegradation and ageing, high biocompatibility and has USP (United States Pharmacopeia) class VI clinical approval for unrestricted use in chronic implants [31]. The micropattern was an array of linear microchannels, 25  $\mu\text{m}$  deep, with a groove width of 60  $\mu\text{m}$  and a terrace width of 10  $\mu\text{m}$ , which allowed to direct axonal and neurite growth without disturbing cell differentiation. To favour cell adhesion, these PDMS substrates were treated in  $\text{O}_2$  plasma for 2 minutes and then coated with polylysine (100  $\mu\text{g}/\text{ml}$ ; Sigma-Aldrich) and laminin (40  $\mu\text{g}/\text{ml}$ ; Sigma-Aldrich).

#### 2.1.2. hNSC cell culture and seeding on 3D micropatterned surface

Biopsies from the temporal lobe and SVZ were obtained from individuals undergoing neurosurgery for epilepsy treatment ( $N = 10$ ). All procedures were performed with informed patient consent, authorized by our local human ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer Toulouse I) in accordance with institutional guidelines on human tissue handling and use. To isolate potential neural progenitor/stem cells, cell suspensions were rapidly obtained by tissue enzymatic digestion and amplified as neurospheres, as already described [18].

At the end of the amplification phase, the neurospheres were dissociated, to obtain single-cell suspensions, and used for direct cell graft or for cell seeding on the 3D micropatterned implants[29]. hNSCs were seeded at a final density of 125 000 cells/ $\text{cm}^2$  on one side of the

1 PDMS, and the day after on the other side, representing 20 000 cells per implant. To obtain the  
2 final neural implant, cells were cultured for 3 days before implantation, with NGF (20 ng/ml;  
3 Peprotech) to favour neuronal differentiation [18].  
4  
5  
6  
7  
8

## 9 **2.2. Animals, M1 lesion induction and implantation**

10 All the animals ( $N = 61$ ) were maintained and treated according to Council of the European  
11 Communities guidelines (Directive of 24 November 1986, 86/609/EEC). This protocol was  
12 approved by the « Direction départementale de la Protection des Populations de la Haute-  
13 Garonne (authorization no. 31125507) » and the « Comité d'éthique pour l'expérimentation  
14 animale Midi-Pyrénées ». All efforts were made to minimize the number of animals used and  
15 to avoid suffering.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Adult female (300-350g) Sprague-Dawley rats (Elevage Janvier, Le Genest-St-Isle, France)  
27 were anaesthetized with ketamine/medetomidine (36/0.47 mg/kg, intraperitoneal injection) and  
28 premedicated with long-acting oxytetracycline (60 mg/kg) and methylprednisolone 0.4 mg/kg).  
29 Cortical lesions focused on the caudal forelimb motor area (M1) were induced by malonate  
30 injection (5  $\mu$ L, 3M solution, pH 7.4 in PBS; Sigma-Aldrich, France) ,  $n = 53$ ) or PBS for the  
31 sham group ( $n = 8$ ) [27] at the following stereotaxic coordinates: 2.5 mm lateral to Bregma, and  
32 2 mm deep. Only animals that displayed substantial neurological dysfunctions (grip strength  
33 below 60% of prelesion value,  $n = 46$  out of 53 lesioned rats) 1 week after injury were selected  
34 (Fig. 1). Then, animals that showed excessive spontaneous recovery in 1 week (grip strength  
35 improvement in one week  $\geq 50\%$  of post-lesion value) were discarded ( $n = 9$  out of 46). Finally,  
36 thirty-seven rats were randomly assigned to the different treated groups  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Two weeks after the lesion, a second surgical intervention for the implantation was then  
54 performed under inhalational anaesthesia with 1.5% isoflurane (Virbac, France) in 100% O<sub>2</sub>.  
55  
56  
57

58 A group of lesioned rats each received five implants preseeded with a total of 100 000 hNSCs  
59  
60  
61  
62  
63  
64  
65

1 in the lesion (hNSC-Implants group,  $n = 15$ ). Another group of lesioned animals each received  
2 five implants without any cells (Implants Alone group,  $n = 6$ ) and another group underwent the  
3 same surgery, but the implants were immediately removed (Sham Implants group,  $n = 10$ ). The  
4 final group of lesioned rats received a cell graft of  $5 \times 10^5$  hNSCs, by perfusion of 5  $\mu$ l of cell  
5 suspension at 1  $\mu$ l/min (hNSCs group,  $n = 6$ ), as already described elsewhere [27].  
6  
7  
8  
9  
10  
11  
12  
13

### 14 **2.3. Grip strength test**

16 Before the study, the animals were acclimatized and trained on a controlled diet for the  
17 behavioural tests, as already described [27]. Behavioural testing to detect motor deficits was  
18 performed one week before lesion (baseline), then 48 hr post-lesion, 24 hr post-graft and once  
19 a month for 3 months after the insult. Experimenters were blind to the treatment group.  
20  
21  
22  
23  
24  
25  
26

27 All the rats underwent strength testing (3 trials/paw/day) with the grip strength test, on three  
28 consecutive days, and a mean score was calculated for each of the six different time points.  
29 Postlesional performances of the contralesional forelimb were expressed as a percentage of the  
30 prelesional baseline value. Each value reported here represents the median  $\pm$  interquartile range  
31 [first quartile: Q1; third quartile: Q3] of each group.  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **2.4. Post-mortem MRI and global atrophy measurement**

42 Either the whole animal anesthetized or just the brain was scanned on a 3T Achieva (Phillips)  
43 MRI scanner. Horizontal and coronal T2-weighted images were acquired (TR: 2 s; TE: 81 ms,  
44 impulsion angle: 90°, FOV: 200 mm, matrix: 176 \* 150, voxel size: 0.34 x 0.34 x 0.8 mm).  
45  
46  
47  
48  
49  
50

51 Hemispheric volume was determined using MRICro on the horizontal slices. Hemispheric  
52 atrophy was then calculated using the following formula:  
53  
54  
55

$$56 \text{ Atrophy (\%)} = \frac{(\text{Healthy hemisphere volume} - \text{Lesioned hemisphere volume})}{\text{Healthy hemisphere volume}} \times 100$$

57  
58  
59  
60  
61  
62  
63  
64  
65

## 2.5. Tissue processing, fluorescence immunolabelling and quantification

### 2.5.1. Tissue processing

After induction of anaesthesia, rats were perfused intracardially with 4% paraformaldehyde solution. Then, brains were embedded in 3% low gelling temperature agarose (Sigma-Aldrich). To preserve biomaterials, thick horizontal brain sections (500  $\mu\text{m}$ ) were cut on a vibratome. For fluorescence immunolabelling, section levels were identified using the Paxinos and Watson [32] atlas, after binocular observations. Sections of the same brain level were subsequently taken for each marker in all animals. Free-floating sections were permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PB for 40 min at room temperature, and incubated with blocking solution (3% goat serum). Sections were then allowed to react with primary antibodies for 48 hours at 4°C, using the appropriate dilution: goat anti-nestin 1:300 (SantaCruz); goat anti-DCX 1:200 (SantaCruz); mouse anti-Tuj1 1:500 (neuron-specific class III beta-tubulin, Covance); rabbit anti-Tuj1 1:300 (Covance); rabbit anti-MAP2 1:200 (microtubule associated protein 2, Millipore); mouse anti-SMI312 1:500 (Abcam); rabbit anti-NeuN 1:300 (neuronal nuclear antigen, Abcam); rabbit anti-GFAP 1:1000 (glial fibrillary acidic protein, DAKO); and rabbit anti-CD68 1:300 (ED1, Millipore). Detection and characterization of the grafted hNSCs were performed using the mouse anti-hMTCO2 1:300 (Abcam) or mouse anti-hNCAM 1:200 (SantaCruz) human markers, in combination with another primary antibody (as specified). After PB washes, the appropriate secondary antibody (Alexa Fluor 488 or 568, Molecular Probes) was incubated for 24 hr at 4 °C. Nuclei were stained with DAPI (0.25  $\mu\text{g}/\text{ml}$ ; Sigma-Aldrich). Negative controls were performed for all immunostainings. [The specificity of the two anti-human antibodies has been checked in our experiments by including sections, run in parallel, from a control group without grafted cells.](#)

### 2.5.2. Image acquisition and quantification

1 Brightfield and fluorescence images were captured using a fluorescence stereo-microscope  
2 (Axiozoom V16; Zeiss) and a confocal microscope (LSM 710; Zeiss) for zoomed images.  
3

4 To analyse the injured area, brightfield images of the whole-brain sections were examined. The  
5 reconstruction percentage, essentially corresponding to implants together with the newly  
6 generated tissue, was measured as follows. First, a volume called the total reorganized volume  
7 and corresponding to the lesion cavity, newly reorganized tissue, implants and dilated ventricle  
8 was estimated using imageJ. To better estimate the initial lesion volume, the mean volume of  
9 normal ventricles derived from six healthy brains ( $1.61 \pm 0.54$  mm) was subtracted. A third  
10 volume, the cavity volume, including the lesion cavity and the dilated ventricle was evaluated.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 The reconstruction percentage for each group was then calculated as follows:

$$22 \text{Reconstruction percentage} = \frac{(Total\ reorganized\ volume - Cavity\ volume)}{(Total\ reorganized\ volume - Normal\ ventricle\ volume)} \times 100$$

23  
24  
25  
26  
27 Immunostaining quantifications were performed with MorphoStrider (ExploraNova, France)  
28 on images taken with the same parameters for each staining. Given the thickness of the sections,  
29 quantification of surviving cells was not possible.  
30  
31  
32  
33

34 For ED1 and GFAP expression analyses, signals were assessed on four independent fields  
35 (2.3x) surrounding the lesion on four sections per animal and five different animals per group.  
36  
37

38 The presence of activated microglia was expressed as the number of ED1-positive cells per  
39  $\text{mm}^2$  of analysed tissue and the astroglial signal was expressed as GFAP-positive surface per  
40  $\text{mm}^2$  of analysed tissue.  
41  
42  
43  
44  
45

46 To estimate the level of grafted cell differentiation, single- and double-stained cells, were  
47 counted using imageJ (cell counter plugin) on axiozoom images (2.3x) for implants or on  
48 confocal images (63x) for tissue analyses. Counting was performed on five independent fields  
49 per animal, and expressed as a percentage of differentiation.  
50  
51  
52  
53  
54  
55  
56  
57  
58

## 59 **2.6. Statistics**

1 Data were analysed with a linear mixed effect model and function using the R software (3.3.3  
2 version) [33]. Time and groups were fixed as factors and interaction between time and group  
3 was analysed in the Anova. Each rat was considered as a random factor. Post-hoc contrast  
4 analyses were done at each time using the least square means approach (MASS and lsmeans  
5 package, function `contr.sdif`) [34]. All other data (immunostaining quantification) were  
6 analysed using GraphPad Prism v. 6.01 software and the nonparametric Kruskal-Wallis test  
7 followed by Dunn's test.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **3. RESULTS**

#### 20 **3.1. Long-term strength improvements with neuro-implants.**

21  
22 The corticostriatal lesion induced motor deficit of the contralesional paw. The grip test provides  
23 a sensitive quantitative measure of the forelimb (Fig. 2A). Post-lesional performances of the  
24 contralesional forepaw were very similar across all the lesioned groups, falling to around 34,2%  
25 [28.0; 42.0]. There was a highly significant time effect, group effect and an interaction between  
26 time and group ( $p < 10^{-6}$ ). Comparison with the hNSCs rats showed that hNSCs-Implants  
27 significantly improved spontaneous recovery from the first month onwards ( $p < 0.05$ ), and then  
28 at 2 and 3 months ( $p < 0.002$  and  $p < 0.05$ ) with a maximum median performance of 83,8%  
29 [79.7; 90.9]. Nevertheless, they remained significantly different from the Sham-lesioned rats ( $p$   
30  $< 0.0001$ ). By contrast, the Implants Alone group at 3 months did not differ statistically from  
31 neither the Sham Implants ( $p = 0.46$ ) nor the hNSCs groups ( $p = 0.33$ ). This result suggests that  
32 the presence of the implant in the lesion cavity did not have any deleterious long-term effect on  
33 spontaneous recovery. Even so, a direct graft of 500 000 hNSCs was unable to enhance the  
34 recovery kinetics compared with hNSC-Implants with only 100 000 cells. These data suggest  
35 that the combination of the implants with the hNSCs is needed to bring about a therapeutic  
36 effect.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3.2. Hemispheric atrophy reduction and tissue reconstruction after neuro-implant engraftment

Injection of malonate led to lesions that induced a cavity at 3 months on T2-weighted MRI and a dilation of the ipsilesional lateral ventricle both hyperintense on T2 images at 3 months (Fig. 2B, Lesioned). In addition, measures of the two hemispheric volumes showed that injury was accompanied by an atrophy of 6.8% [3.9; 9.8] at 3 months for the lesioned group (Sham Implants, Fig. 2C). In the implanted groups, T2 images confirmed that the implants, apparent as black rectangles, were still located at the core of the lesion after 3 months (Fig. 2B, Implanted). The presence of implants limited atrophy and dilation of ventricle. Atrophy was non-significantly decreased to 2.2% [1.3; 7.6] for the Implants Alone group and significantly to 2.1% [-0.4; 2.7] for the hNSC-Implants group compared with the Sham Implants group ( $p < 0.05$ ; Fig. 2C). The collapse of brain tissue was reduced by a mechanical effect of PDMS devices and brain morphology tended to be preserved. To further analyse the impact of the implants on tissue regeneration, histological brain sections were performed. 500  $\mu\text{m}$ -thick sections were a good compromise between keeping the implants in place as often as possible during the cutting and carrying out the immunostaining. Analysis of whole sections by light microscopy demonstrated a consistent matching with MR images for the lesion cavity and dilated ventricle (Fig. 3A). Dilation of the ventricle was impressive in the Sham Implants group. In contrast to the MRI slices, the implants were not always directly observable, but left a rectangular print that was visible on these brightfield sections and was surrounded by newly regenerated tissue, notably in the hNSC-Implants group (Fig. 3B). In the Sham Implants group, the newly generated tissue represented just 19.3% [10.1; 20.3] of the reorganized volume, so reconstruction was limited 3 months post lesion. The Implants Alone group had the same profile, with 22.1% [20.0; 24.5] of reconstruction, suggesting that simply inserting implants in

1 the core lesion is not sufficient to improve tissue generation. By contrast, reconstruction was  
2 better in the hNSC-Implants group, and represented 32.5% ([31.5; 39.0],  $p < 0.05$ ) showing that  
3  
4 this combination stimulated tissue reconstruction around the injured area.  
5  
6  
7  
8

### 9 **3.3. Immunohistological characterization of brain tissue regeneration**

10 Examination of all stained sections from implanted lesioned animals with specific human  
11 markers revealed long-term survival of hNSCs (Fig. 4A), compared with the poor survival  
12 observed following hNSCs transplantation (Fig. 4B). Indeed, less than 10 surviving cells were  
13 found in the hNCSs group and no reconstructed tissue was seen, thus this group was not fully  
14 explored in this study. In the hNSC-implants group, at 3 months post-lesion, hNCAM and  
15 hMTCO2-immunoreactive cells were numerous, both near the implantation site and in the  
16 perilesional host tissue (Fig. 4A, top). No solid tumour-like growth was observed with the  
17 grafted cells judging from the human immunostaining. When hNSCs were co-grafted with  
18 implants, they spread from the implants to the reconstructed tissues and the close perilesional  
19 host tissues, sometimes over quite long distances (see below), often along blood vessels (white  
20 arrows; Fig. 4A). Furthermore, they were found to be intermingled with newly generated Tuj1-  
21 positive neurons from the host (Fig. 4A, bottom).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 **3.3.1. Neuronal fate and host-scaffold interactions**

44 The fate of the grafted cells was first studied on the implants, by direct immunostaining on the  
45 neuro-implants retrieved after rat sacrifice (Fig. 5). Considerable cell density was still found on  
46 implants at 3 months, homogeneously distributed after insertion in the lesion (Fig. 5A).  
47 Interestingly, the cells were in the grooves and expressed mature neuronal markers such as  
48 NeuN, MAP2, and SMI312. Their axonal network was well established along the straight  
49 microchannels (SMI312, Fig. 5A) as has previously been observed in vitro [28].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Double staining study, using specific human markers, confirmed the presence of grafted cells,  
2 and revealed that cells from the host were also present on the implants above all when hNSCs  
3 had been pre-seeded (Fig. 5B). Some hNSCs were still expressing immature neural markers  
4 after 3 months. The proportion of hNCAM- and nestin-positive double-labelled cells was 51%.  
5  
6 A total of 28% of hNSCs were also Tuj1-positive and, interestingly, 27% had been able to  
7 mature and express neuronal markers as NeuN. Most of the *host* cells observed on the implants  
8 expressed immature markers (nestin, DCX and Tuj1; Fig. 5B). However, a few expressed  
9 MAP2 (Fig. 5A), demonstrating a process of maturation, especially when hNSCs were on the  
10 implants as well. Differentiation of both hNSCs and progenitor cells from the host were  
11 observed on the PDMS scaffolds emphasising the positive interaction with the biomaterial.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **3.3.2. Short-distance migration of grafted cells**

25 Many grafted hNSCs were also found migrating to and integrating with the host tissue, close to  
26 implant location, in the reconstructed and perilesional tissues (Fig. 6, white arrowhead:  
27 hNCAM+ fibres). A total of 33% of these cells remained immature (nestin+ cells), even at 3  
28 months, but 32% were engaged in a neuronal differentiation pathway (Tuj1+; Fig. 6, top). A  
29 large proportion of the cells that succeeded in colonizing the host tissue became mature neurons  
30 (22% MAP2+ and 26% NeuN+; Fig. 6, bottom).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **3.3.3. Specific and long-distance migration of grafted cells**

45 Finally, in the host tissue, some grafted cells were detected both in the peri-lesional area,  
46 notably in deep layers of perilesional motor cortices M1, M2, S1-jaw and S1-upper limb (Fig.  
47 7;  $n = 2$ ), and far away from the implantation/lesion site, the precise location depending on the  
48 animal. In the rats studied by histology ( $n = 5$ ), a large proportion of hNSCs were found deep  
49 in the lesion, in the caudate-putamen area at the dorso-ventral coordinates (-4.60 to -5.80 mm  
50 from Bregma) (Fig. 7). They were also detected stucked to the choroid plexus of the lateral  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

ventricle ( $n=5$ ). In these areas, the cells retained a stemness characteristic, as they expressed the immature marker nestin. Unexpectedly, in some animals, a few migrant grafted cells were found deep below the lesion, in other brain structures such as the thalamus (AV: Antero-ventral/ VPL: Ventral-posterolateral/ VPM: Ventral-posteromedial nucleus;  $n = 2$ ) and the caudal hippocampus, 5 mm behind Bregma, in the CA3 layer ( $n = 2$ ). In these host functional structures, the cells were integrated with the tissue as new mature neurons (NeuN+). hNSCs have therefore an integration potential in the host tissue.

### 3.4. Inflammation

An inflammatory and astroglial reaction was visible in all groups 3 months after induction of the lesion, and formed a glial scar around the lesion (ED1- and GFAP-positive cells, Fig. 8A). In the Sham Implants group, 18.6% of the analysed tissue was GFAP-positive (Fig. 8B). The astroglial reaction was also detectable, albeit less intense, when the animals received implants without hNSCs (16.1% of the analysed tissue,  $p < 0.05$ ), suggesting good biocompatibility of PDMS implants. A fraction of the seeded hNSCs were able to differentiate into astrocytes (hNCAM+; Fig. 8D), but there were too few of them to contribute much to glial scar formation. In any case, the combination of implants with neuronal cells prevented glial scar formation and considerably reduced the astroglial reaction (10.5% of analysed tissue) compared with the Sham Implants ( $p < 0.0001$ ), and Implants Alone ( $p < 0.05$ ) groups. Regarding the microglial activation initially caused by the lesion, PDMS implants with or without grafted cells did not seem to have any impact (Fig. 8C).

## 4. DISCUSSION

These results demonstrate for the first time an improvement in motor recovery following engraftment of microstructured scaffolds with pre-seeded primary adult hNSCs, compared with other treatments such as direct cell graft or scaffold-alone insertion. This study confirms the

1 results previously obtained with the neuronal cell line hNT2 pre-seeded on the same scaffolds  
2 [29], and provides new insights into the underlying mechanisms behind this behavioural  
3 improvement. Both grafted and host cells were found on implants at 3 months, despite the quite  
4 hostile environment of the lesion. Implant insertion stimulated tissue reconstruction in the  
5 injured area, notably in the presence of hNSCs, which could differentiate into mature neurons.  
6 These supported host neurogenesis, and limited atrophy and glial reaction. Finally, some hNSCs  
7 showed targeted migration and neuronal maturation abilities in cerebral structures close and  
8 away from the implantation site.  
9

#### 10 **4.1. Multiple bioimplant effects on tissue reorganization and motor recovery**

11 Olstorn *et al.* [24] described the tremendous potential of adult hNSCs to migrate towards the  
12 lesion and to mature into neurons. To our knowledge, however, our study was the first time that  
13 adult hNSCs had been grafted intra-cerebrally in combination with biomaterials. The beneficial  
14 effect on behaviour was more significant and more prominent than a direct graft of five times  
15 more cells. Even if cells taken from adult brains have limited proliferation ability, they can  
16 survive on PDMS without any added growth factors or nutrients released by a degradable  
17 material. One reason for this survival is that the 3D microstructures of the device protect the  
18 cells during implantation, and the 3 days pre-seeding of the cells certainly limits the latency  
19 period that is often observed after a direct cell graft [29]. Therefore, this engraftment had led to  
20 tissue reconstruction filling 32.5% of the lesion. The effect was better than that of other  
21 approaches, which have achieving maximum reconstruction of around 5% [35,36], but not as  
22 good as the effect of Matrigel™ mixed with cells, which reconstructed around 50% of the lesion  
23 [21]. Owing to its undefined composition, however, Matrigel™ is not suitable for clinical  
24 applications [37].  
25

26 In the present study, we also showed that the presence of PDMS implants had further beneficial  
27 effects. First, the scaffolds restricted hemispheric atrophy by sustaining tissue and limited  
28

1 dilation of the ipsilesional lateral ventricle. The brain/cerebral morphology was therefore  
2 preserved. This effect has also been observed in another study, 60 days after lesion of the  
3 cerebral cortex [38]. Maintaining the integrity of the brain shape is undoubtedly an important  
4 process, as it certainly avoids damage aggravation. Perilesional areas and callosal fibres are key  
5 structures for natural plasticity, which promotes particularly forelimb sensorimotor functional  
6 recovery [39]. Second, implant insertion reduced the glial reaction, especially when hNSCs  
7 were present. Moreover, the presence of co-grafted hNSCs has been shown to have a tendency  
8 to reduce the inflammatory reaction, as they downregulate the expression of chemokines such  
9 as TNF- $\alpha$ , IL-6 and IL-1 $\beta$  [20] and make the environment less hostile. The establishment of a  
10 glial scar after a stroke is a normal process, and has several benefits, including protecting neural  
11 cells and restricting the spread of inflammation [40,41]. By contrast, a very large glial scar acts  
12 as a barrier, precludes passage of chemoattractant signals and, consequently, of cells and thus  
13 prevents all possibility of reconstruction [42–44]. In our study, astroglial activation was  
14 significantly less intense, and there was a tiny glial scar around the lesion cavity in the hNSC-  
15 Implants group, which may favour reconstruction.

#### 36 **4.2. Bidirectional interactions with the host tissue and neuronal maturation**

37 In the present study, cells from the host tissue could be detected on the biomaterial 3 months  
38 after implantation in the lesion. This attraction has been observed with scaffolds of different  
39 compositions, notably PLA [45], PLGA [15,46], gelatin-siloxane hybrid [38] and collagen [35].  
40 The biomaterial in our study may have favoured hNSC differentiation in the brain by mimicking  
41 the extracellular matrix. It also acted as a scaffold for endogenous neuroblasts that had migrated  
42 up to the infarct area. Their maturation into neurons was better in the presence of hNSCs than  
43 on implants alone. This neurotrophic effect has already been described [47,48], and grafted  
44 cells have been shown to be capable of making new connections with host tissue cells [49].  
45 Consequently, both populations are perhaps responsible for the effect in functional recovery.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Grafted hNSCs were able to mature on implants and around the lesion site. Nevertheless, some  
2 of the grafted hNSCs around the lesion site remained immature. Even 3 months post-lesion, the  
3  
4 mechanisms of endogenous neurogenesis, migration and reconstruction still seemed to be in  
5  
6 progress, possibly suggesting that recovery could improve with time. Our serial behavioural  
7  
8 assessment allowed us to show that a greater sensorimotor improvement occurred not  
9  
10 immediately after the implantation, but 2 months post-lesion, which might be explained by a  
11  
12 reconstruction effect rather than just a trophic effect.  
13  
14  
15

### 16 **4.3. Short- and long-distance migration**

17  
18 Some hNSCs migrated from the implants to the surrounding host tissue. They were often found  
19  
20 close to blood vessels, even at 3 months post-lesion, in agreement with other studies  
21  
22 demonstrating that the vascular network can guide stem-cell migration [50,51]. Thored et al.  
23  
24 found neuroblasts migrating toward the ischaemic area, in the vicinity of blood vessels, up to  
25  
26 16 weeks post-infarct [52]. Moreover, after migration, endothelial cells stimulate self-renewal  
27  
28 and promote the maturation of neural stem cells in the tissue [53,54]. This could explain our  
29  
30 finding that a subset of co-grafted hNSCs succeeded in maturing around the lesion and in the  
31  
32 host tissue. Another part of grafted-hNSCs stayed in an immature or quiescent state in the  
33  
34 choroid plexus which is a component of the adult SVZ niche that could support their  
35  
36 proliferation [55].  
37  
38  
39  
40  
41  
42

43 A lesion of the primary motor cortex induces a motor deficit by degenerating fibres of the  
44  
45 corticospinal tract (CST), and creates secondary degeneration, indicated by the presence of  
46  
47 pyknotic nuclei, mostly in thalamic motor nuclei (VPL, VPM). [MCP-1 is a critical molecule in](#)  
48  
49 [the regulation of thalamic retrograde neuronal degeneration \[56\]](#). The thalamus is involved in  
50  
51 the integration of sensory afferents and receives cortical motor efferent signals, playing a major  
52  
53 role in the sensory motor loop. In our study, neuro-implants were inserted in the dorso-ventral  
54  
55 axis to promote restoration of the sensorimotor loop. Some grafted hNSCs were able to migrate  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 and integrate these secondary degenerated thalamic nuclei and become mature neurons (NeuN+  
2 cells), whereas they usually remain at the injection site in a healthy brain [49]. The implant  
3 position cannot alone explain migration to the thalamus. Chemotactic molecules may attract  
4 cells. The molecular mechanisms involved in directing the new neurons to the damaged areas  
5 revealed the role of blood vessels (endothelial cells) and inflammatory cells (reactive astrocyte  
6 and activated microglia), involving well-described factors such as stromal cell-derived factor 1  
7 (SDF-1), BDNF, monocyte chemoattractant protein-1 (MCP-1), osteopontin and VEGF [7,57].  
8  
9 Gaillard et al. showed that connections can be established between a transplant of embryonic  
10 cortical neurons in the primary motor cortex and thalamus [58]. These cell  
11 migrations/integrations and the design of neuro-implants can provide advantages to restore the  
12 CST and corticothalamic tracts, and could explain the enhanced motor strength with  
13 hNSC-Implants. It should be emphasised that migrant cells were mainly found in the  
14 ipsilesional hemisphere. Few hNSCs have migrated and integrated the caudal hippocampus  
15 (CA3). As far as we are aware, this is the first time that intra-cortically grafted cells were  
16 observed to have migrated to the caudal hippocampus, a few millimetres from the lesion. This  
17 could bring new assets for motor recovery, especially for postlesional motor relearning, as the  
18 hippocampus has been found to be involved in motor learning [59].  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **4.4. Conclusions**

42  
43 The combined insertion of hNSCs and implants may help the motor recovery. The role of this  
44 association is multiple. Implants have sustained cerebral tissue allowing the preservation of  
45 adjacent cortical areas which could be involved in natural plasticity. The presence of implants  
46 had permitted the survival and maturation of both grafted hNSC and endogenous neuroblasts,  
47 favouring the tissue reconstruction. Moreover, the reduction of astroglial reaction has led to a  
48 better bidirectional exchanges between the implants and the host tissue. Tissue reconstruction  
49 and neuroblast maturation seem still ongoing 3 months post injury. This therapeutic strategy  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 with long-lasting bioimplants seems to give an advantage over too rapidly biodegradable  
3 biomaterials regarding cell viability [60] and bring new hope for future applications.  
4  
5

## 6 7 **Abbreviations:**

8  
9 AV = anteroventral thalamic nucleus

10  
11 DCX = doublecortin

12  
13 GFAP= glial fibrillary acidic protein

14  
15 hMTCO2 = human mitochondria marker (cytochrome c oxidase II)

16  
17 hNCAM = human neural cell adhesion molecules

18  
19 hNSC = human neural stem cells

20  
21 M1 = primary motor cortex

22  
23 MAP2 = microtubule associated protein 2

24  
25 NeuN = neuronal nuclear antigen

26  
27 NGF = neural growth factor

28  
29 PDMS = polydimethylsiloxane

30  
31 SMI312 = anti-neurofilament marker

32  
33 Tuj1= neuron-specific class III beta-tubulin

34  
35 VPL = ventral posterolateral thalamic nucleus

36  
37 VPM = ventral posteromedial thalamic nucleus  
38  
39  
40  
41  
42  
43  
44  
45

## 46 **Declarations**

### 47 - **Ethical Approval and Consent to participate**

48  
49 Neural stem cells: All procedures were performed with informed patient consent, authorized by  
50  
51 our local human ethics committee, the local board of the Health Agency (“Agence Régionale  
52  
53 de Santé Occitanie”): Comité de Protection des Personnes Sud-Ouest et Outre Mer Toulouse I)  
54  
55  
56  
57  
58 in accordance with institutional guidelines on human tissue handling and use.  
59  
60  
61  
62  
63  
64  
65

1 Authorization from the Ministry of Education and Research for working on human samples to  
2 Prof JC Sol, neurosurgery department of Toulouse, number DC-2009-903 and modification  
3  
4 number DC-2016-2629.  
5  
6

7 All the animals were maintained and treated according to Council of the European Communities  
8  
9 guidelines (Directive of 24 November 1986, 86/609/EEC). This protocol was approved by the  
10  
11 « Direction départementale de la Protection des Populations de la Haute-Garonne (authorization  
12  
13 no. 31125507) » and the « Comité d'éthique pour l'expérimentation animale Midi-Pyrénées ».  
14  
15  
16

17  
18  
19 - **Consent for publication**

20 Not applicable  
21  
22  
23  
24  
25

26 - **Availability of supporting data**

27 Raw data supporting this article can be sent by e-mail upon request.  
28  
29  
30  
31  
32  
33

34 - **Competing interests**

35 The authors declare that they have no competing interests.  
36  
37  
38  
39  
40

41 - **Funding**

42 ITAV-CNRS (Institut des Techniques Avancées). SFR (Société Fédérative de Recherche) Institut Des  
43  
44 Sciences Du Cerveau De Toulouse. Région Midi-Pyrénées. Fondation Institut de France NRJ.  
45  
46  
47  
48  
49

50 - **Authors' contributions**

51 Carole Davoust was the doctoral student in charge of all the protocol and performed  
52  
53 behavioural, surgical, MRI, immunohistological and statistical experiments.  
54  
55

56 Benjamin Plas was a master student who performed a part of the behavioural and surgical  
57  
58 protocol.  
59  
60  
61  
62  
63  
64  
65

1 Amélie Bédurier and Boris Demain were doctoral students who designed and made the  
2 biomaterials.

3 Anne-Sophie Salabert was a student who help for the imaging experiments.  
4

5 Jean-Christophe Sol was the neurosurgeon who provided the human samples.  
6

7 Chistophe Vieu was the senior physicist who elaborated the biomaterials.  
8

9 Laurence Vaysse was in charge of the cell culture on the scaffolds and on the  
10 immunohistological protocol.  
11

12 Carole Davoust, Laurence Vaysse and Isabelle Loubinoux analysed the data and wrote the  
13 paper.  
14

15 Isabelle Loubinoux conceived the research project of a guiding biomaterials for brain injuries,  
16 was in charge of the fund raising, of the behavioural and MRI experiments and conducted the  
17 study.  
18  
19  
20  
21

## 22 - **Acknowledgements**

23  
24  
25 The authors are grateful to H el ene Gros-Dagnac and Nathalie Vayssi ere (INSERM/UPS  
26 UMR1214 MRI platform) for their technical assistance. Thanks to Sophie Allart (INSERM  
27 1043) and C ecile Pouzet (CNRS-FRAIB), both members of the Genotoul-TRI platform,  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 66 - **Authors' information**

67 Carole Davoust<sup>a</sup>, Benjamin Plas<sup>a,c</sup>, Am elie B edurier<sup>b</sup>, Boris Demain<sup>a</sup>, Anne-Sophie Salabert<sup>a,c</sup>,

68 Jean Christophe Sol<sup>a,c</sup>, Christophe Vieu<sup>b</sup>, Laurence Vaysse<sup>a</sup>, Isabelle Loubinoux<sup>a</sup>

69 <sup>a</sup>ToNIC, Toulouse NeuroImaging Center, Universit e de Toulouse, Inserm, UPS, France

70 <sup>b</sup>LAAS-CNRS, Universit e de Toulouse, CNRS, INSA, UPS, Toulouse, France

71 <sup>c</sup>Centre Hospitalier Universitaire de Toulouse; P ole Neurosciences ; CHU Toulouse, France

## REFERENCES

1. Riquelme PA, Drapeau E, Doetsch F. Brain micro-ecologies: neural stem cell niches in the adult mammalian brain. *Philos. Trans. R. Soc. B Biol. Sci.* 2008;363:123–37.
2. Ma DK, Bonaguidi MA, Ming G, Song H. Adult neural stem cells in the mammalian central nervous system. *Cell Res.* 2009;19:672–82.
3. Gross CG. Neurogenesis in the adult brain: death of a dogma. *Nat. Rev. Neurosci.* 2000;1:67–73.
4. Doetsch F. The glial identity of neural stem cells. *Nat. Neurosci.* 2003;6:1127–34.
5. Nam H, Lee K-H, Nam D-H, Joo KM. Adult human neural stem cell therapeutics: Current developmental status and prospect. *World J. Stem Cells.* 2015;7:126–36.
6. Thored P, Arvidsson A, Cacci E, Ahlenius H, Kallur T, Darsalia V, et al. Persistent Production of Neurons from Adult Brain Stem Cells During Recovery after Stroke. *Stem Cells.* 2006;24:739–47.
7. Lindvall O, Kokaia Z. Neurogenesis following Stroke Affecting the Adult Brain. *Cold Spring Harb. Perspect. Biol.* 2015;7:a019034.
8. Zhang R, Zhang Z, Wang L, Wang Y, Gousev A, Zhang L, et al. Activated Neural Stem Cells Contribute to Stroke-Induced Neurogenesis and Neuroblast Migration toward the Infarct Boundary in Adult Rats. *J. Cereb. Blood Flow Metab.* 2004;24:441–8.
9. Osman AM, Porritt MJ, Nilsson M, Kuhn HG. Long-Term Stimulation of Neural Progenitor Cell Migration After Cortical Ischemia in Mice. *Stroke.* 2011;42:3559–65.
10. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat. Med.* 2002;8:963–70.
11. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. *Ann. Neurol.* 2002;52:802–13.
12. Saha B, Peron S, Murray K, Jaber M, Gaillard A. Cortical lesion stimulates adult subventricular zone neural progenitor cell proliferation and migration to the site of injury. *Stem Cell Res.* 2013;11:965–77.
13. Hicks C, Stevanato L, Stroemer RP, Tang E, Richardson S, Sinden JD. In Vivo and In Vitro Characterization of the Angiogenic Effect of CTX0E03 Human Neural Stem Cells. *Cell Transplant.* 2013;22:1541–52.
14. Michelsen KA, Acosta-Verdugo S, Benoit-Marand M, Espuny-Camacho I, Gaspard N, Saha B, et al. Area-Specific Reestablishment of Damaged Circuits in the Adult Cerebral Cortex by Cortical Neurons Derived from Mouse Embryonic Stem Cells. *Neuron.* 2015;85:982–97.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
15. Quittet M-S, Touzani O, Sindji L, Cayon J, Fillesoye F, Toutain J, et al. Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat. *Acta Biomater.* 2015;15:77–88.
  16. Braun H, Günther-Kern A, Reymann K, Onteniente B. Neuronal differentiation of human iPS-cells in a rat cortical primary culture. *Acta Neurobiol Exp.* 2012;72:219–229.
  17. Moe MC, Varghese M, Danilov AI, Westerlund U, Ramm-Petersen J, Brundin L, et al. Multipotent progenitor cells from the adult human brain: neurophysiological differentiation to mature neurons. *Brain.* 2005;128:2189–99.
  18. Vaysse L, Labie C, Canolle B, Jozan S, Bédurier A, Arnauduc F, et al. Adult human progenitor cells from the temporal lobe: Another source of neuronal cells. *Brain Inj.* 2012;26:1636–45.
  19. Westerlund U, Svensson M, Moe MC, Varghese M, Gustavsson B, Wallstedt L, et al. Endoscopically Harvested Stem Cells: A Putative Method in Future Autotransplantation: Neurosurgery. 2005;779–84.
  20. Huang L, Wong S, Snyder EY, Hamblin MH, Lee J-P. Human neural stem cells rapidly ameliorate symptomatic inflammation in early-stage ischemic-reperfusion cerebral injury. *Stem Cell Res. Ther.* 2014;5.
  21. Jin K, Mao X, Xie L, Galvan V, Lai B, Wang Y, et al. Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* 2010;30:534–44.
  22. Guan J, Zhu Z, Zhao RC, Xiao Z, Wu C, Han Q, et al. Transplantation of human mesenchymal stem cells loaded on collagen scaffolds for the treatment of traumatic brain injury in rats. *Biomaterials.* 2013;34:5937–46.
  23. André EM, Passirani C, Seijo B, Sanchez A, Montero-Menei CN. Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington’s disease. *Biomaterials.* 2016;83:347–62.
  24. Olstorn H, Varghese M, Murrell W, Moe MC, Langmoen IA. Predifferentiated brain-derived adult human progenitor cells migrate toward ischemia after transplantation to the adult rat brain. *Neurosurgery.* 2011;68:213–22.
  25. Nakaji-Hirabayashi T, Kato K, Iwata H. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier. *Biomaterials.* 2009;30:4581–9.
  26. Elias PZ, Spector M. Implantation of a collagen scaffold seeded with adult rat hippocampal progenitors in a rat model of penetrating brain injury. *J. Neurosci. Methods.* 2012;209:199–211.
  27. Vaysse L, Conchou F, Demain B, Davoust C, Plas B, Ruggieri C, et al. Strength and fine dexterity recovery profiles after a primary motor cortex insult and effect of a neuronal cell graft. *Behav. Neurosci.* 2015;129:423.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
28. Bédurier A, Vieu C, Arnauduc F, Sol J-C, Loubinoux I, Vaysse L. Engineering of adult human neural stem cells differentiation through surface micropatterning. *Biomaterials*. 2012;33:504–14.
  29. Vaysse L, Beduer A, Sol JC, Vieu C, Loubinoux I. Micropatterned bioimplant with guided neuronal cells to promote tissue reconstruction and improve functional recovery after primary motor cortex insult. *Biomaterials*. 2015;58:46–53.
  30. Bédurier A, Vaysse L, Flahaut E, Seichepine F, Loubinoux I, Vieu C. Multi-scale engineering for neuronal cell growth and differentiation. *Microelectron. Eng.* 2011;88:1668–71.
  31. Hassler C, Boretius T, Stieglitz T. Polymers for neural implants. *J. Polym. Sci. Part B Polym. Phys.* 2011;49:18–33.
  32. Paxinos G, Watson C. *The Rat Brain in Stereotaxic Coordinates*, 4th ed. Academic Press. Academic Press; 1998.
  33. Baayen RH, Davidson DJ, Bates DM. Mixed-effects modeling with crossed random effects for subjects and items. *J. Mem. Lang.* 2008;59:390–412.
  34. Theory and Computational Methods for Linear Mixed-Effects Models. *Mix.-Eff. Models - PLUS* [Internet]. Springer New York; 2000 [cited 2017 May 12]. p. 57–96. Available from: [http://link.springer.com/chapter/10.1007/0-387-22747-4\\_2](http://link.springer.com/chapter/10.1007/0-387-22747-4_2)
  35. Lu D, Mahmood A, Qu C, Hong X, Kaplan D, Chopp M. Collagen scaffolds populated with human marrow stromal cells reduce lesion volume and improve functional outcome after traumatic brain injury. *Neurosurgery*. 2007;61:596.
  36. Qu C, Xiong Y, Mahmood A, Kaplan DL, Goussev A, Ning R, et al. Treatment of Traumatic Brain Injury in Mice with Bone Marrow Stromal Cell-Impregnated Collagen Scaffolds. *J. Neurosurg.* 2009;111:658–65.
  37. Wong Po Foo CTS, Lee JS, Mulyasmita W, Parisi-Amon A, Heilshorn SC. Two-component protein-engineered physical hydrogels for cell encapsulation. *Proc. Natl. Acad. Sci. U. S. A.* 2009;106:22067–72.
  38. Deguchi K, Tsuru K, Hayashi T, Takaishi M, Nagahara M, Nagotani S, et al. Implantation of a new porous gelatin–siloxane hybrid into a brain lesion as a potential scaffold for tissue regeneration. *J. Cereb. Blood Flow Metab.* 2006;26:1263–1273.
  39. Starkey ML, Bleul C, Zorner B, Lindau NT, Mueggler T, Rudin M, et al. Back seat driving: hindlimb corticospinal neurons assume forelimb control following ischaemic stroke. *Brain*. 2012;135:3265–81.
  40. Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, et al. Astrocyte scar formation aids central nervous system axon regeneration. *Nature*. 2016;532:195–200.
  41. Burda JE, Sofroniew MV. Reactive Gliosis and the Multicellular Response to CNS Damage and Disease. *Neuron*. 2014;81:229–48.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
42. Menet V, Prieto M, Privat A, y Ribotta MG. Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. *Proc. Natl. Acad. Sci.* 2003;100:8999–9004.
  43. Silver J, Miller JH. Regeneration beyond the glial scar. *Nat. Rev. Neurosci.* 2004;5:146–56.
  44. Peruzzotti-Jametti L, Donegá M, Giusto E, Mallucci G, Marchetti B, Pluchino S. The role of the immune system in central nervous system plasticity after acute injury. *Neuroscience.* 2014;0:210–21.
  45. Álvarez Z, Castaño O, Castells AA, Mateos-Timoneda MA, Planell JA, Engel E, et al. Neurogenesis and vascularization of the damaged brain using a lactate-releasing biomimetic scaffold. *Biomaterials.* 2014;35:4769–81.
  46. Bible E, Chau DYS, Alexander MR, Price J, Shakesheff KM, Modo M. The support of neural stem cells transplanted into stroke-induced brain cavities by PLGA particles. *Biomaterials.* 2009;30:2985–94.
  47. Cossetti C, Alfaro-Cervello C, Donegà M, Tyzack G, Pluchino S. New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies. *Cell Tissue Res.* 2012;349:321–9.
  48. Lu P, Jones LL, Snyder EY, Tuszynski MH. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. *Exp. Neurol.* 2003;181:115–29.
  49. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. *Proc. Natl. Acad. Sci. U. S. A.* 2004;101:11839–44.
  50. Koutsakis C, Kazanis I. How Necessary is the Vasculature in the Life of Neural Stem and Progenitor Cells? Evidence from Evolution, Development and the Adult Nervous System. *Front. Cell. Neurosci.* [Internet]. 2016 [cited 2016 Mar 8];10. Available from: <http://journal.frontiersin.org/Article/10.3389/fncel.2016.00035/abstract>
  51. Kojima T, Hirota Y, Ema M, Takahashi S, Miyoshi I, Okano H, et al. Subventricular Zone-Derived Neural Progenitor Cells Migrate Along a Blood Vessel Scaffold Toward the Post-Stroke Striatum. *Stem Cells.* 2010;28:545–54.
  52. Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O. Long-Term Neuroblast Migration Along Blood Vessels in an Area With Transient Angiogenesis and Increased Vascularization After Stroke. *Stroke.* 2007;38:3032–9.
  53. Ohab JJ, Fleming S, Blesch A, Carmichael ST. A neurovascular niche for neurogenesis after stroke. *J. Neurosci. Off. J. Soc. Neurosci.* 2006;26:13007–16.
  54. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, et al. Endothelial Cells Stimulate Self-Renewal and Expand Neurogenesis of Neural Stem Cells. *Science.* 2004;304:1338–40.

1 55. Silva-Vargas V, Maldonado-Soto AR, Mizrak D, Codega P, Doetsch F. Age-Dependent  
2 Niche Signals from the Choroid Plexus Regulate Adult Neural Stem Cells. *Cell Stem Cell*.  
3 2016;19:643–52.

4 56. Muessel MJ, Berman NE, Klein RM. Early and specific expression of monocyte  
5 chemoattractant protein-1 in the thalamus induced by cortical injury. *Brain Res*.  
6 2000;870:211–221.

7  
8  
9 57. Wang Y, Deng Y, Zhou G-Q. SDF-1 $\alpha$ /CXCR4-mediated migration of systemically  
10 transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. *Brain*  
11 *Res*. 2008;1195:104–12.

12  
13 58. Gaillard A, Prestoz L, Dumartin B, Cantereau A, Morel F, Roger M, et al.  
14 Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons.  
15 *Nat. Neurosci*. 2007;10:1294–9.

16  
17  
18 59. Albouy G, Sterpenich V, Baiteau E, Vandewalle G, Desseilles M, Dang-Vu T, et al. Both  
19 the Hippocampus and Striatum Are Involved in Consolidation of Motor Sequence Memory.  
20 *Neuron*. 2008;58:261–72.

21  
22  
23 60. Wong FSY, Chan BP, Lo ACY. Carriers in Cell-Based Therapies for Neurological  
24 Disorders. *Int. J. Mol. Sci*. 2014;15:10669–723.

## 25 26 27 28 29 **Figure Legends**

30  
31  
32 **Fig. 1. Flowchart of the study.**

33  
34  
35  
36  
37 **Fig. 2. Functional recovery and evaluation of hemispheric atrophy with neuro-implants**  
38 **inserted in a brain lesion.**

39  
40  
41  
42 (A) Grip strength performance at different time points after transplantation of neuro-implants  
43 pre-seeded with hNSC cells (hNSC-Implants,  $n = 15$ ), or implants on their own (Implants  
44 Alone,  $n = 8$ ), or direct engraftment of a neural cell suspension (hNSCs, 500 000 cells,  $n = 6$ ).  
45 Controls were sham-operated for the lesion (Sham,  $n = 8$ ) or implantation (Sham Implants,  $n =$   
46 10). A statistical analysis was carried out with a linear mixed effect model (significant  
47 differences are reported on the graph at 2 and 3 months, \*  $p < 0.05$ ). (B) Representative  
48 horizontal T2-weighted MRI images in a Sham Implants (Lesioned) and an Implants Alone  
49 (Implanted) rat. L = lesion, V = ventricle. Red arrows indicate PDMS implants. (C) Percentage  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 of atrophy of the lesioned hemisphere in each group, as assessed on T2 MRI images. Data  
2 represent individual values and median  $\pm$  interquartile range. A statistical analysis was carried  
3  
4 out with the Kruskal-Wallis test, followed by Dunn's test. \*  $p < 0.05$ .  
5  
6  
7  
8

9 **Fig. 3. Effect of PDMS implants on tissue reconstruction 3 months after lesion.**

10  
11 (A) Comparison between horizontal, histological and MRI slices in a representative rat of each  
12 group (lesioned area in white). Implants were visible on MRI slices (red arrowheads). Most of  
13 the time, only the position of the implant was observable on the histological slices (black  
14 arrowheads), surrounded by newly generated tissue (yellow arrows). A-P: antero-posterior axis,  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

D-V: dorso-ventral axis. Scale bar: 500  $\mu$ m. (B) Representative horizontal brain section of the lesioned area under brightfield illumination from Implants Alone (left) and hNSC-Implants rats (right). The newly generated tissue (yellow arrow) was mostly located around the PDMS implants which could still be found in place in the lesion core after cutting (red arrowhead). V = ventricle; I = implant position. Red ROI: total volume (lesion cavity, dilated ventricle, newly reorganized tissue around implants); Green ROI: cavity volume (lesion cavity and dilated ventricle) Scale bar: 1 mm. (C) The percentage of reconstruction was calculated on brightfield images in each group. Data represent individual value and median  $\pm$  interquartile range. Statistical analysis was carried out with the Kruskal-Wallis test, followed by Dunn's test. \*  $p < 0.05$ .

66 **Fig. 4. A. hNSCs location and survival around neuro-implants 3 months after graft.**

67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

hNSCs were identified by two specific human markers (in red), hMTCO2 or hNCAM, in combination with a marker (in green) of immature (Tuj-1) or mature (NeuN) neurons. Low magnification is provided on the left and higher magnification, corresponding to the area in the white square, on the right. White arrows indicate blood vessels (Axiozoom images, scale bar:

100µm). **B. hNSCs detection 3 months after a graft of hNSCs alone.** hNSCs were identified in red by hMTCO2 and in green by Tuj-1. Low magnification is provided on the left and higher magnification, corresponding to the area in the white square, on the right. White arrows indicate rare surviving hNSCs among a cluster of non-bright fluorescent cells corresponding certainly to non-alive cells (Axiozoom images, scale bar: 100µm). V: ventricle. L: lesion.

**Fig. 5. Immunofluorescence staining of hNSCs on neuro-implants 3 months after engraftment.** (A) Typical distribution of hNSCs and their neuritic network on the PDMS scaffold stained with the neuronal markers (in green) NeuN (top), SMI312 (middle) and MAP2 (bottom). Scale bar: 500 µm and 20 µm. (B) Detection of cell differentiation after 3 months on implants pre-seeded with hNSC (hNSC-Implants) or on their own (Implants Alone). Single or double staining was performed as indicated, with the human markers hMTCO2 or hNCAM (in red) and markers for immature (nestin and Tuj1 in green and DCX in red) and mature (NeuN in green) neurons. Nuclei were counterstained with DAPI. White arrowheads indicate marker colocalization and arrows single marker expression. Axiozoom images, Scale bar: 20µm.

**Fig. 6. Immunofluorescence characterization of hNSC differentiation in reconstructed and in the host perilesional tissues.** Double staining was performed as indicated, with human markers (hMTCO2 or hNCAM) and markers for immature (nestin and Tuj1) and mature (MAP2 and NeuN) neurons. Representative double staining is shown at a higher magnification in the insets. Nuclei were counterstained with DAPI. White arrows indicate blood vessels, white arrowheads indicate human fibres, and asterisks localise typical double staining. Confocal images, scale bar: 20µm.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Fig. 7. Localization of migrant hNSCs grafted in the brain on implants, detected by immunofluorescence staining.** Identification of the migration area on three axial slices (Paxinos and Watson atlas) at Bregma coordinates: - 3.60 mm, -4.60 mm and -5.82 mm. The lesion is indicated by a blue circle on slices of the whole brain, and red rectangles represent the implants. hNSCs were identified by the specific human markers (in red: hMTCO2 and hNCAM, in combination with different markers of maturation (in green: nestin, Tuj1 or NeuN). The names of the structures are indicated at the level where hNSCs were retrieved. AV = anteroventral thalamic nucleus; CA3 = CA3 field of hippocampus; ChP = choroid plexus; CPu = caudate/putamen; M1 = primary motor cortex; M2 = secondary motor cortex; S1 = primary somatosensory cortex; VPM = ventral-posteromedial thalamic nucleus; VPL = ventral posterolateral thalamic nucleus.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Fig. 8. Assessment of astrocyte and inflammation reaction near cystic cavity and implantation site.** (A) Typical appearance of fluorescent immunostaining for GFAP, the astroglial marker (in green), and ED1, a cellular marker specific to activated microglia, monocytes and macrophages (in red) on Axiozoom images. White squares indicate higher magnification area of insets. Scale bar: 500  $\mu$ m. (B) Immunostaining quantification of the astroglial signal: data are expressed as the surface of GFAP-positive signal per mm<sup>2</sup> of tissue analysed in each group ( $n = 5$  per group). (C) Number of ED1 immunoreactive cells per mm<sup>2</sup> of tissue analysed ( $n = 5$  per group). Data represent median  $\pm$  interquartile range. Values were analysed with the Kruskal-Wallis test followed by a corrected Dunn's test. \*  $p < 0.05$ . \*\*\* $p < 0.0001$ . (D) Immunofluorescence detection of host or human astrocytes in the tissue of rats with hNSC-Implants 3 months post graft. Astrocytes (GFAP) appear in green and hNSCs (hNCAM) in red. Representative double staining is shown at higher magnification. Scale bar: 50  $\mu$ m. L = lesion; V = ventricle.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65




A









B






C












A




B







Perilesional tissues

M1/S1




Cpu: Caudate Putamen




Distant tissues

AV/VPL/VPM: Thalamus



ChP : Choroid Plexus



CA3 Hippocampus

